Skip to main content

Table 1 Patient characteristics

From: Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

 

EC

EP

Overall

(N = 800)

(N = 505)

(N = 1305)

Age

 Median [min, max]

63.5 [38.3, 86.2]

60.0 [28.0, 78.0]

62.0 [28.0, 86.2]

 Missing data

6 (0.8%)

0 (0%)

6 (0.5%)

Sex

 Female

266 (33.2%)

138 (27.3%)

404 (31.0%)

 Male

528 (66.0%)

367 (72.7%)

895 (68.6%)

 Missing data

6 (0.8%)

0 (0%)

6 (0.5%)

ECOG PS

 0–1

733 (91.6%)

451 (89.3%)

1184 (90.7%)

 2

62 (7.8%)

50 (9.9%)

112 (8.6%)

 Missing data

5 (0.6%)

4 (0.8%)

9 (0.7%)

BMI

 Underweight

31 (3.9%)

16 (3.2%)

47 (3.6%)

 Normal

347 (43.4%)

228 (45.1%)

575 (44.1%)

 Overweight

271 (33.9%)

181 (35.8%)

452 (34.6%)

 Obese

148 (18.5%)

79 (15.6%)

227 (17.4%)

 Missing data

3 (0.4%)

1 (0.2%)

4 (0.3%)

SAE

 0

493 (61.6%)

215 (42.6%)

708 (54.3%)

 1

287 (35.9%)

134 (26.5%)

421 (32.3%)

 Missing data

20 (2.5%)

156 (30.9%)

176 (13.5%)

AE

 1

715 (89.4%)

419 (83.0%)

1134 (86.9%)

 2

716 (89.5%)

439 (86.9%)

1155 (88.5%)

 3

545 (68.1%)

295 (58.4%)

840 (64.4%)

 4

231 (28.9%)

148 (29.3%)

379 (29.0%)

 5

70 (8.8%)

36 (7.1%)

106 (8.1%)

 Missing data

20 (2.5%)

9 (1.8%)

29 (2.2%)

Highest AEa

 1

29 (3.6%)

32 (6.3%)

61 (4.7%)

 2

152 (19.0%)

127 (25.1%)

279 (21.4%)

 3

322 (40.2%)

162 (32.1%)

484 (37.1%)

 4

207 (25.9%)

139 (27.5%)

346 (26.5%)

 5

70 (8.8%)

36 (7.1%)

106 (8.1%)

 Missing data

20 (2.5%)

9 (1.8%)

29 (2.2%)

  1. Abbreviations: EC etoposide plus carboplatin, EP etoposide plus cisplatin, ECOG Eastern Cooperative Oncology Group, PS performance status, BMI body mass index, SAE serious adverse event, AE adverse event
  2. arefers to the highest grade of adverse events in one patient